title: Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: most patients should be treated.
authors.affiliation: Center for Liver Diseaes, Inova Fairfax Hospital, Falls Church, Virginia, USA.
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Koff
authors.forename: Zobair
authors.initials: Z
authors.lastname: Younossi
mesh_terms: D000410:Alanine Transaminase / Q000032:analysis*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003657:Decision Making; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008111:Liver Function Tests; D008297:Male; D011379:Prognosis; D011994:Recombinant Proteins; D012016:Reference Values; D012254:Ribavirin / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index; D014481:United States / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D000410:Alanine Transaminase